Amgen (AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
AMGN Hot Sheet
Overall Analyst Rating:NEUTRAL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +9.5%
Amgen (Nasdaq: AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
